Entrada Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 5, 2024

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Collaboration revenue	$19,570	$43,735	$173,384	$87,165
Operating expenses:
Research and development	31,257	22,191	91,900	71,593
General and administrative	9,971	7,532	28,606	23,639
Total operating expenses	41,228	29,723	120,506	95,232
(Loss) income from operations	(21,658)	14,012	52,878	(8,067)
Other income:
Interest and other income	5,766	4,051	14,346	10,926
Total other income	5,766	4,051	14,346	10,926
(Loss) income before provision for income taxes	(15,892)	18,063	67,224	2,859
(Benefit from) provision for income taxes	(1,860)	(17,398)	2,729	—
Net (loss) income	$(14,032)	$35,461	$64,495	$2,859
Net (loss) income per share, basic	$(0.35)	$1.07	$1.79	$0.09
Net (loss) income per share, diluted	$(0.35)	$1.02	$1.72	$0.08
Weighted‑average common shares outstanding, basic	40,629,602	33,281,287	36,118,930	32,942,958
Weighted‑average common shares outstanding, diluted	40,629,602	34,775,451	37,583,486	34,289,411
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	1,301	509	777	1,561
Total other comprehensive income (loss)	1,301	509	777	1,561
Total comprehensive (loss) income	$(12,731)	$35,970	$65,272	$4,420

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.